Hemostatic Agents Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Nov 2018| TMR1056A| Transparency

Sample Report

Report Highlights

Hemostatic Agents Market - Overview

Hemostasis is the physiological process to stop the bleeding, or blood flow via a blood vessel, or hemorrhage. A clot is formed at injury site in hemostasis and results in repairing of blood vessels. The main components of hemostasis are primary hemostasis, secondary hemostasis, and fibrinolysis. At the time of a blood vessel injury, platelets gather together to form a plug. In hemostasis, an interaction of proteins, known as clotting factors, forms a fibrin mesh to hold the platelets intact, thereby resulting in the injury healing while not letting the blood escape from the blood vessel. Hemostatic agents are utilized to stem blood flow and enhance clotting and hemostasis by speeding up the coagulation process. These agents enhance hemostasis by progressing primary hemostasis, boosting the formation of fibrin, or inhibiting fibrinolysis. Hemostatic agents play a prominent and vital role in the treatment or prevention of excessive or disruptive blood flow, thereby indicating their importance and use in treatments in various therapeutic areas. According to JEMS (Journal of Emergency Medical Services), traumatic and non-traumatic causes of hemorrhage carry remarkable morbidity and mortality.

Rise in the geriatric population, increase in number of surgical procedures, research & developments, and advancements in the fields of healthcare and life sciences, rise in public health awareness and measures have led to the introduction of appropriate and effective treatments for diseases. Consistent rise in geriatric population requiring treatments in various therapeutic areas fuels the demand for hemostatic agents in order to prevent the disruptive blood loss. This provides significant opportunity for key players operating in the market. Key players are introducing different strategies of launching products and acquisitions, along with appropriate marketing and strong distributors and hospitals network, thereby boosting the hemostatic agents market.

Acquisition and collaboration of related companies, along with the launch of new products after extensive research and development activities, has been a key strategy adopted by key players to strengthen their geographic presence in the last few years. Therefore, the players strive to gain competitive advantage in the market by opting for strategies such as agreements, partnerships and collaborations, and new product development.

The global hemostatic agents market has been broadly segmented based on product type, specialty / therapeutic area, size of hospitals, and region. In terms of product type, the global hemostatic market has been divided into active agents, passive agents, and combination. The active agents segment, followed by the combination segment, is expected to expand during the forecast period. In terms of specialty / therapeutic area, the global hemostatic agents market has been classified into cardiology, cath lab, trauma, general surgery, obgyn, transplant, oncology, neurology, orthopedic, plastic surgery, dental, and others (urological surgeries, pulmonary surgeries). General surgery, cardiology, and trauma, segments are expected to dominate the market during the forecast period due to the increase in number of patient population cases in these therapeutic areas. In terms of size of hospitals, the global hemostatic agents market has been divided into large hospitals (500+ bed size), medium hospital (250-499 beds), and small hospitals (less than 250 beds). Large hospitals and medium hospitals segments are expected to hold a major share of the market during the forecast period.

In terms of region, the global hemostatic agents market has been segmented into North America, Europe, Asia Pacific, South Africa and Rest of World (RoW). North America and Europe holds a prominent share of the global hemostatic agents market. The market in North America is primarily driven by the increase in geriatric population, rise in number of surgical procedures, and increase in patient population. The market in Asia Pacific is expected to expand at a significant growth rate during the forecast period. The report also states key players in the market based on various attributes such as company overview, key business strategies, financial overview, recent developments, and product portfolio. Key players functioning in the global hemostatic agents market include Baxter, Ethicon US, LLC., C. R. Bard, Inc., B. Braun Melsungen AG, Pfizer Inc., Z-Medica, LLC., CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

The global hemostatic agents market has been segmented as mentioned below:

Global Hemostatic Agents Market, by Product Type
Active Agents
Passive Agents
Combination

Global Hemostatic Agents Market, by Specialty / Therapeutic Area
Cardiology
Cath Lab
Trauma
General Surgery
ObGyn
Transplant
Oncology
Neurology
Orthopedic
Plastic Surgery
Dental
Others (Urological Surgeries, Pulmonary Surgeries)

Global Hemostatic Agents Market, by Size of Hospitals
Large Hospitals (500+ bed size)
Medium Hospital (250-499 beds)
Small Hospitals (less than 250 beds)

Global Hemostatic Agents Market, by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Australia
Japan
South Korea
Rest of Asia Pacific
South Africa
Rest of World (RoW)

Table 1 : Hemostatic Agents Market Value (US$ Mn), by Regions, 2015–2022
Table 2 : Pricing Analysis - U.S.
Table 3 : Pricing Analysis - Canada
Table 4 : Pricing Analysis - Germany
Table 5 : Pricing Analysis - France
Table 6 : Pricing Analysis - U.K.
Table 7 : Pricing Analysis - Spain
Table 8 : Pricing Analysis - Italy
Table 9 : Pricing Analysis - China
Table 10 : Pricing Analysis - India
Table 11 : Pricing Analysis - Australia
Table 12 : Pricing Analysis - Japan
Table 13 : Pricing Analysis - South Korea
Table 14 : Pricing Analysis - South Africa
Table 15 : Comparative Assessment of Key Products
Table 16 : U.S. Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 17 : U.S. Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 18 : Brand Assessment:Most Popular Hemostatic Brands - U.S.
Table 19 : Criss-cross Assessment – Product vs. Specialty – U.S.
Table 20 : Selection Criteria for Products, by Specialty / Therapeutic Area - U.S.
Table 21 : U.S. Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 22 : Concentration of Hospitals in U.S., by State
Table 23 : Detailed Hospital Segmentation in U.S., by Bed Size
Table 24 : Canada Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 25 : Canada Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 26 : Brand Assessment:Most Popular Hemostatic Brands - U.S.
Table 27 : Criss-cross Assessment – Product vs. Specialty – Canada
Table 28 : Selection Criteria for Products, by Specialty / Therapeutic Area - Canada
Table 29 : Canada Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 30 : Concentration of Hospitals in Canada, by State
Table 31 : Detailed Hospital Segmentation in Canada, by Bed Size
Table 32 : Germany Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 33 : Germany Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 34 : Brand Assessment:Most Popular Hemostatic Brands - Germany
Table 35 : Criss-cross Assessment – Product vs. Specialty – Germany
Table 36 : Selection Criteria for Products, by Specialty / Therapeutic Area - Germany
Table 37 : Germany Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 38 : Concentration of Hospitals in Germany, by State
Table 39 : Detailed Hospital Segmentation in Germany, by Bed Size
Table 40 : France Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 41 : France Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 42 : Brand Assessment:Most Popular Hemostatic Brands - France
Table 43 : Criss-cross Assessment – Product vs. Specialty – France
Table 44 : Selection Criteria for Products, by Specialty / Therapeutic Area - France
Table 45 : France Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 46 : Concentration of Hospitals in France, by State
Table 47 : Detailed Hospital Segmentation in France, by Bed Size
Table 48 : U.K. Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 49 : U.K. Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 50 : Brand Assessment: Most Popular Hemostatic Brands - U.K.
Table 51 : Criss-cross Assessment – Product vs. Specialty – U.K.
Table 52 : Selection Criteria for Products, by Specialty / Therapeutic Area - U.K.
Table 53 : U.K. Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 54 : Concentration of Hospitals in U.K., by State
Table 55 : Detailed Hospital Segmentation in U.K., by Bed Size
Table 56 : Spain Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 57 : Spain Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 58 : Brand Assessment: Most Popular Hemostatic Brands - Spain
Table 59 : Criss-cross Assessment – Product vs. Specialty – Spain
Table 60 : Selection Criteria for Products, by Specialty / Therapeutic Area - Spain
Table 61 : Spain Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 62 : Concentration of Hospitals in Spain, by State
Table 63 : Detailed Hospital Segmentation in Spain, by Bed Size
Table 64 : Italy Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 65 : Italy Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 66 : Brand Assessment: Most Popular Hemostatic Brands - Italy
Table 67 : Criss-cross Assessment – Product vs. Specialty – Italy
Table 68 : Selection Criteria for Products, by Specialty / Therapeutic Area - Italy
Table 69 : Italy Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 70 : Concentration of Hospitals in Italy, by State
Table 71 : Detailed Hospital Segmentation in Italy, by Bed Size
Table 72 : China Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 73 : China Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 74 : Brand Assessment: Most Popular Hemostatic Brands - China
Table 75 : Criss-cross Assessment – Product vs. Specialty – China
Table 76 : Selection Criteria for Products, by Specialty / Therapeutic Area - China
Table 77 : China Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 78 : Concentration of Hospitals in China, by State
Table 79 : Detailed Hospital Segmentation in China, by Bed Size
Table 80 : India Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 81 : India Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 82 : Brand Assessment: Most Popular Hemostatic Brands - India
Table 83 : Criss-cross Assessment – Product vs. Specialty – India
Table 84 : Selection Criteria for Products, by Specialty / Therapeutic Area - India
Table 85 : India Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 86 : Concentration of Hospitals in India, by State
Table 87 : Detailed Hospital Segmentation in India, by Bed Size
Table 88 : Australia Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 89 : Australia Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 90 : Brand Assessment: Most Popular Hemostatic Brands - Australia
Table 91 : Criss-cross Assessment – Product vs. Specialty – Australia
Table 92 : Selection Criteria for Products, by Specialty / Therapeutic Area - Australia
Table 93 : Australia Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 94 : Concentration of Hospitals in Australia, by State
Table 95 : Detailed Hospital Segmentation in Australia, by Bed Size
Table 96 : Japan Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 97 : Japan Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 98 : Brand Assessment: Most Popular Hemostatic Brands - Japan
Table 99 : Criss-cross Assessment – Product vs. Specialty – Japan
Table 100 : Selection Criteria for Products, by Specialty / Therapeutic Area - Japan
Table 101 : Japan Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 102 : Concentration of Hospitals in Japan, by State
Table 103 : Detailed Hospital Segmentation in Japan, by Bed Size
Table 104 : South Korea Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 105 : South Korea Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 106 : Brand Assessment: Most Popular Hemostatic Brands - South Korea
Table 107 : Criss-cross Assessment – Product vs. Specialty – South Korea
Table 108 : Selection Criteria for Products, by Specialty / Therapeutic Area - South Korea
Table 109 : South Korea Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 110 : Concentration of Hospitals in South Korea, by State
Table 111 : Detailed Hospital Segmentation in South Korea, by Bed Size
Table 112 : South Africa Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 113 : South Africa Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 114 : Brand Assessment: Most Popular Hemostatic Brands - South Africa
Table 115 : Criss-cross Assessment – Product vs. Specialty – South Africa
Table 116 : Selection Criteria for Products, by Specialty / Therapeutic Area - South Africa
Table 117 : South Africa Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 118 : Concentration of Hospitals in South Africa, by State
Table 119 : Detailed Hospital Segmentation in South Africa, by Bed Size
Table 120 : Rest of the World (RoW) Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 121 : Rest of the World (RoW) Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 122 : Rest of the World (RoW) Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022

Figure 1 : Hemostatic Agents Market Value (US$ Mn), 2015–2022
Figure 2 : Global Hemostatic Agents Market Share Analysis (2017)
Figure 3 : Selection Criteria for Distributors- U.S.
Figure 4 : Selection Criteria for Distributors - Canada
Figure 5 : Selection Criteria for Distributors - Germany
Figure 6 : Selection Criteria for Distributors - France
Figure 7 : Selection Criteria for Distributors - U.K.
Figure 8 : Selection Criteria for Distributors - Spain
Figure 9 : Selection Criteria for Distributors - Italy
Figure 10 : Selection Criteria for Distributors - China
Figure 11 : Selection Criteria for Distributors - India
Figure 12 : Selection Criteria for Distributors - Australia
Figure 13 : Selection Criteria for Distributors - Japan
Figure 14 : Selection Criteria for Distributors - South Korea
Figure 15 : Selection Criteria for Distributors - South Africa
Figure 16 : Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 17 : Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 18 : Johnson & Johnson Breakup of Net Sales, by Region, 2017
Figure 19 : Johnson & Johnson Breakup of Net Sales (%), by Business Segment, 2017
Figure 20 : Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 21 : Baxter R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 22 : Baxter Breakup of Net Sales, by Region, 2017
Figure 23 : Baxter Breakup of Net Sales (%), by Business Segment, 2017
Figure 24 : Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 25 : Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 26 : Pfizer, Inc. Breakup of Net Sales, by Business Segment, 2017
Figure 27 : Pfizer, Inc. Breakup of Net Sales (%), by Region, 2017
Figure 28 : CryoLife, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 29 : CryoLife, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 30 : CryoLife, Inc. Breakup of Net Sales, by Region, 2017
Figure 31 : CryoLife, Inc. Breakup of Net Sales (%), by Business Segment, 2017
Figure 32 : C. R. Bard, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 33 : C. R. Bard, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 34 : C. R. Bard, Inc. Breakdown of Net Sales, by Region, 2016
Figure 35 : C. R. Bard, Inc. Breakdown of Net Sales (%), by Business Segment, 2016
Figure 36 : CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 37 : CSL Behring R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 38 : CSL Behring Net Profit, Y-o-Y, 2014-2017
Figure 39 : CSL Behring Breakdown of Net Sales (%), by Business Segment, 2017
Figure 40 : B. Braun Melsungen AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 41 : B. Braun Melsungen AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 42 : B. Braun Melsungen AG Breakdown of Net Sales (%), by Region, 2017
Figure 43 : B. Braun Melsungen AG Breakdown of Net Sales (%), by Business Segment, 2017
Figure 44 : Takeda Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
Figure 45 : Takeda Pharmaceutical R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
Figure 46 : Takeda Pharmaceutical Sales, by Region, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Hemostatic Agents Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Report Highlights

FAQ